Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab

Rituximab is a pioneering anti-CD20 monoclonal antibody that became the first-line drug used in immunotherapy of B-cell malignancies over the last twenty years. Rituximab activates the complement system in vitro, but there is an ongoing debate on the exact role of this effector mechanism in therapeu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Felberg, Anna, Taszner, Michał, Urban, Aleksandra, Majeranowski, Alan, Jaskuła, Kinga, Jurkiewicz, Aleksandra, Stasiłojć, Grzegorz, Blom, Anna M., Zaucha, Jan M., Okrój, Marcin
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710700/
https://ncbi.nlm.nih.gov/pubmed/33329558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.584509
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados